The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC).
 
Mark A. Socinski
No Relationships to Disclose
 
Alexander Luft
No Relationships to Disclose
 
Aleksandra Szczesna
No Relationships to Disclose
 
Wojciech Szafranski
No Relationships to Disclose
 
Rinat Galiulin
No Relationships to Disclose
 
Beatrix Bálint
No Relationships to Disclose
 
Keunchil Park
Honoraria - AstraZeneca; Clovis Oncology; Kyowa Hakko Kirin; Lilly; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Kyowa Hakko Kirin; Lilly; Roche Pharma AG
Research Funding - AstraZeneca; Sanofi
 
Martin Reck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Proacta
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Proacta
 
Henrik Depenbrock
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Shivani Nanda
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Travel, Accommodations, Expenses - Lilly
 
Nadia Chouaki
Employment - Lilly
Leadership - Clinical Research Physician
Stock and Other Ownership Interests - Lilly
 
Nick Thatcher
Honoraria - Lilly
Consulting or Advisory Role - Lilly
Speakers' Bureau - Lilly